PRE
Prenetics Global·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 0
Consensus Rating "Buy"
Ample Liquidity
Low Beta
Bullish Abandoned Baby
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About PRE
Prenetics Global Limited
A Hong Kong-based company that provides diagnostic, genetic testing, and related services to the healthcare industry
Unit 701-706, K11 Atelier King’s Road, 728 King’s Road, Quarry Bay, Hong Kong
--
Prenetics Global Limited was incorporated in the Cayman Islands in 2014. The company is a global diagnostic and genetic testing company whose mission is to ensure the health and rational use of healthcare services for millions of people around the world by making the three pillars of prevention, diagnosis and personalized care comprehensive and available to anyone anytime, anywhere. Led by visionary entrepreneur Danny Yeung, the company operates in nine locations including the UK, Hong Kong, India, South Africa and Southeast Asia. The company develops consumer genetic testing and early colorectal cancer screening; provides COVID 19 testing, rapid point-of-care and home diagnostic testing, and medical genetic testing.
Company Financials
EPS
PRE has released its 2025 Q3 earnings. EPS was reported at -0.41, versus the expected -0.55, beating expectations. The chart below visualizes how PRE has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
PRE has released its 2025 Q3 earnings report, with revenue of 23.55M, reflecting a YoY change of 567.66%, and net profit of -8.69M, showing a YoY change of 27.96%. The Sankey diagram below clearly presents PRE's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
